Leerink Partners analyst Marc Goodman reiterated a Buy rating on Evolus (EOLS – Research Report) on March 5 and set a price target of $25.00.
Marc Goodman has given his Buy rating due to a combination of factors that highlight Evolus’s strong market position and growth potential. The company reported robust fourth-quarter revenues of $79 million, marking a 30% increase, and provided guidance for 2025 that aligns with these positive trends. A significant contributor to this growth is the Evolus Rewards loyalty program, which has seen consumer enrollment exceed 1.1 million, with approximately 220,000 redemptions in the fourth quarter alone.
Furthermore, the anticipated launch of two new filler lines, Form and Smooth, in the US by early second quarter of 2025 is expected to be a major revenue driver, supporting the company’s ambitious target of $700 million by 2028. The recent FDA approval of Evolysse for facial lines and folds, including wrinkles from weight loss, further strengthens the product’s market appeal. Additionally, the expansion of new accounts, with over 2,900 added in 2024, and the growing membership in the loyalty program underscore the company’s solid market presence and potential for continued growth.
In another report released on March 5, Barclays also maintained a Buy rating on the stock with a $25.00 price target.
EOLS’s price has also changed slightly for the past six months – from $14.980 to $14.170, which is a -5.41% drop .